Marianna Romito, Senior Field Application Scientist and Cell Therapy Specialist for Europe at MaxCyte, supports the scientific activity of customers, collaborators, and prospects. She joined the company in December 2019, after finishing her post-doc on CRISPR-Cas9 and AAV6 HDR-mediated gene correction of IL7RA-deficient hematopoietic stem cells at the UCL Great Ormond Street Institute of Child Health. Her Ph.D. work was focused on the pre-clinical development of HIV-resistant genome-edited T cells using TALEN nucleases at the Albert Ludwig University of Freiburg. Marianna holds two patents on genome and epigenome editing of clinically relevant cells and several publications in high-impact factor journals such as Nature Biotechnology, Nucleic Acids Research, and Nature Communication.
